Bayer Schering Pharma to Open R & D Center in Beijing    

Bayer Schering Pharma, a division of Bayer HealthCare, said on February 12th it will invest Euro 100 million (US$129 million) in a new global research and development center in Beijing over the next five years.
   China is the third largest market worldwide for the Bayer group, and it will become the third country besides Germany and the U.S. to host such a center for its Bayer Schering Pharma unit.
   "We are continuously increasing our presence in the Asia Pacific Region where China is our key growth driver," said Andreas Fibig, chairman of Bayer Schering Pharma's board of management.